StockIQpro
NASDAQ:LAB

Standard Biotools Inc.

Track all markets on TradingView
Track all markets on TradingView

Standard Biotools Inc.'s revenue fell 6.2% in fiscal 2025 to $85.3M while operating margin rose to −129.2%. Free cash flow was −$82.6M, −96.9% of revenue, and the diluted share count rose 8.0%.Summary generated from Standard Biotools Inc.'s SEC filings. Latest annual report filed Mar 16, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$85.3M
Revenue growth−6.2%
Revenue, 5-yr CAGR−9.2%
Gross margin49.9%
Operating margin−129.2%
Net margin−87.8%
ROICn/a
Return on equity−16.7%
Debt / equityn/a
Free cash flow−$82.6M
FCF margin−96.9%
Share count change+8.0%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue131981069185
Operating income−67−116−77−127−110
Net income−59−190−75−139−75
Free cash flow−57−93−46−152−83

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations